Patents by Inventor Thomas Mondritzki

Thomas Mondritzki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240051935
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20230265072
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: April 13, 2023
    Publication date: August 24, 2023
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Patent number: 11472803
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: October 18, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • Publication number: 20220274958
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: February 8, 2022
    Publication date: September 1, 2022
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Patent number: 11298367
    Abstract: The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: April 12, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Carsten Schmeck, Pierre Wasnaire, Heiko Schirmer, Hana Cernecka, Karoline Droebner, Hanna Tinel, Anja Buchmueller, Thomas Mondritzki, Axel Kretschmer, Klemens Lustig, Robert Fricke, Guillaume Levilain, Ursula Krenz, Norbert Witowski
  • Publication number: 20220089591
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 24, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Publication number: 20210261541
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Patent number: 11091463
    Abstract: The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 17, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Anja Buchmueller, Hanna Tinel, Karoline Droebner, Thomas Mondritzki, Heiko Schirmer, Axel Kretschmer, Carsten Schmeck, Pierre Wasnaire, Hana Cernecka
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Patent number: 10927109
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 23, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximilian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • Publication number: 20200339567
    Abstract: The present application relates to novel substituted imidazopyridine amides of the formula (I), to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular, neurological and central nervous as well as metabolic disorders.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 29, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Daniel MEIBOM, Jutta MEYER, Karl COLLINS, Nuria ORTEGA HERNANDEZ, Jan STAMPFUSS, Frank WUNDER, Till FREUDENBERGER, Thomas MONDRITZKI, Nina Alexandra SCHEERER, Kirsten LEINEWEBER, Jens SCHAMBERGER, Alexander STRAUB, Kersten Matthias GERICKE, Walter KROH, Mario LOBELL, Klaus MÜNTER
  • Publication number: 20200338096
    Abstract: The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Application
    Filed: October 17, 2018
    Publication date: October 29, 2020
    Inventors: Marie-Pierre COLLIN-KROEPELIN, Peter KOLKHOF, Thomas NEUBAUER, Chantal FUERSTNER, Elisabeth POOK, Matthias Beat WITTWER, Carsten SCHMECK, Pierre WASNAIRE, Heiko SCHIRMER, Hana CERNECKA, Karoline DROEBNER, Hanna TINEL, Anja BUCHMUELLER, Thomas MONDRITZKI, Axel KRETSCHMER, Klemens LUSTIG, Robert FRICKE, Guillaume LEVILAIN, Ursula KRENZ, Norbert WITOWSKI
  • Patent number: 10815205
    Abstract: The present invention relates to novel 5-(carboxamide)-1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: October 27, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marie-Pierre Collin-Kröpelin, Peter Kolkhof, Thomas Neubauer, Chantal Fürstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Anja Buchmüller, Hanna Tinel, Karoline Dröbner, Thomas Mondritzki, Heiko Schirmer, Axel Kretschmer, Carsten Schmeck, Pierre Wasnaire, Hana Cernecka
  • Publication number: 20200017473
    Abstract: The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 16, 2020
    Inventors: Marie-Pierre COLLIN, Peter KOLKHOF, Thomas NEUBAUER, Chantal FUERSTNER, Elisabeth POOK, Matthias Beat WITTWER, Klemens LUSTIG, Anja BUCHMUELLER, Hanna TINEL, Karoline DROEBNER, Thomas MONDRITZKI, Heiko SCHIRMER, Axel KRETSCHMER, Carsten SCHMECK, Pierre WASNAIRE, Hana CERNECKA
  • Patent number: 10519154
    Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: December 31, 2019
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Henrik Teller, Melissa Boultadakis Arapinis, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Klaus Münter, Thomas Mondritzki, Tobias Marquardt
  • Publication number: 20190367516
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER
  • Patent number: 10472348
    Abstract: The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 12, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marie-Pierre Collin, Peter Kolkhof, Thomas Neubauer, Chantal Fürstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Anja Buchmüller, Hanna Tinel, Karoline Dröbner, Thomas Mondritzki, Heiko Schirmer, Axel Kretschmer, Carsten Schmeck, Pierre Wasnaire, Hana Cernecka
  • Patent number: 10435403
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 8, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexander Straub, Markus Brechmann, Thomas Müller, Mark Meininghaus, Katrin Nowak-Reppel, Hanna Tinel, Klaus Münter, Daniela Fliegner, Thomas Mondritzki, Melissa Boultadakis Arapinis, Tobias Marquardt, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Matthias Beat Wittwer
  • Publication number: 20190263805
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: September 6, 2017
    Publication date: August 29, 2019
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximilian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Publication number: 20190241562
    Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: July 4, 2017
    Publication date: August 8, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Henrik TELLER, Melissa BOULTADAKIS ARAPINIS, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Klaus MÜNTER, Thomas MONDRITZKI, Tobias MARQUARDT